NASDAQ:COYA Coya Therapeutics (COYA) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free COYA Stock Alerts $7.99 -0.01 (-0.13%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$7.82▼$8.3850-Day Range$7.00▼$10.1352-Week Range$3.21▼$10.69Volume37,510 shsAverage Volume62,733 shsMarket Capitalization$116.65 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Coya Therapeutics alerts: Email Address Coya Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside75.2% Upside$14.00 Price TargetShort InterestHealthy1.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.82 out of 5 starsMedical Sector821st out of 910 stocksPharmaceutical Preparations Industry387th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingCoya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCoya Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.53% of the float of Coya Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoya Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coya Therapeutics has recently increased by 309.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCoya Therapeutics does not currently pay a dividend.Dividend GrowthCoya Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COYA. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Coya Therapeutics this week, compared to 2 articles on an average week.Search Interest20 people have searched for COYA on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coya Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.80% of the stock of Coya Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 39.75% of the stock of Coya Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Coya Therapeutics is -10.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coya Therapeutics is -10.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoya Therapeutics has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Coya Therapeutics Stock (NASDAQ:COYA)Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Read More COYA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COYA Stock News HeadlinesApril 22, 2024 | businesswire.comCoya Therapeutics to Participate in the Mizuho Neuroscience SummitApril 18, 2024 | businesswire.comCoya Therapeutics to Participate in the 3rd Annual ALS Drug Development SummitApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 15, 2024 | finance.yahoo.comCoya Therapeutics, Inc. (COYA) Interactive Stock Chart - Yahoo FinanceApril 8, 2024 | businesswire.comCoya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumMarch 27, 2024 | finance.yahoo.comWe're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn RateMarch 21, 2024 | finance.yahoo.comCoya Therapeutics Inc (COYA) Reports Fiscal 2023 Financial Results and Corporate UpdatesMarch 19, 2024 | investorplace.comCOYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023April 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 19, 2024 | finance.yahoo.comCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial ResultsMarch 14, 2024 | investing.comCoya presents promising ALS biomarker data at conferenceMarch 13, 2024 | msn.comNew treatment for ALS provides hope for Maine families battling diseaseMarch 12, 2024 | finance.yahoo.comCoya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology ConferenceMarch 12, 2024 | finance.yahoo.comCoya Therapeutics to Participate in BTIG Fireside DiscussionMarch 10, 2024 | markets.businessinsider.comBuy Recommendation for Coya Therapeutics on Promising Neurodegenerative Disease Treatment ApproachMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Dyne Therapeutics: Promising Clinical Data and Solid Financial Position Fuel OptimismFebruary 29, 2024 | finance.yahoo.comCoya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 ConferenceFebruary 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Treace Medical Concepts (TMCI)February 22, 2024 | msn.comCoya Inches up Ahead of ALS AddressFebruary 22, 2024 | businesswire.comCoya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology ConferenceFebruary 21, 2024 | finance.yahoo.comCoya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a "Pipeline in a Product"February 21, 2024 | businesswire.comCoya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer's Disease and Coya's Pathway to a “Pipeline in a Product”February 13, 2024 | finance.yahoo.comCoya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory DiseasesFebruary 5, 2024 | benzinga.comCoya Therapeutics Secures Key Financing In Its Fight Against Myriad DiseasesFebruary 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Coya Therapeutics Amid Promising Drug Development and Regulatory MilestonesJanuary 29, 2024 | finance.yahoo.comCoya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology ConferenceJanuary 18, 2024 | finance.yahoo.comCoya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call SeriesSee More Headlines Receive COYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today4/23/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:COYA CUSIPN/A CIK1835022 Webwww.coyatherapeutics.com Phone800-587-8170FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$14.00 Low Stock Price Target$14.00 Potential Upside/Downside+75.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,990,000.00 Net MarginsN/A Pretax Margin-121.03% Return on Equity-42.53% Return on Assets-37.57% Debt Debt-to-Equity RatioN/A Current Ratio8.15 Quick Ratio8.15 Sales & Book Value Annual Sales$6 million Price / Sales19.44 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book3.23Miscellaneous Outstanding Shares14,600,000Free Float13,171,000Market Cap$116.65 million OptionableNot Optionable Beta0.80 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Howard Berman Ph.D. (Age 50)Chairman & CEO Comp: $833.75kDr. Fred Grossman D.O. (Age 62)FAPA, President & Chief Medical Officer Comp: $610.63kMr. David S. Snyder (Age 64)CFO & COO Comp: $610.94kDr. Gregory MacMichael Ph.D. (Age 68)Chief Technical Officer Dr. Michelle Frazier Ph.D.Senior Vice President of Regulatory AffairsMr. Aaron Thome Ph.D.Head of Neuroinflammation PlatformDr. Arun Swaminathan Ph.D.Chief Business Development OfficerMore ExecutivesKey CompetitorsCitius PharmaceuticalsNASDAQ:CTXRSocietal CDMONASDAQ:SCTLOptiNoseNASDAQ:OPTNImmunicNASDAQ:IMUXRepare TherapeuticsNASDAQ:RPTXView All CompetitorsInstitutional OwnershipGreenlight Capital Inc.Bought 805,959 shares on 2/15/2024Ownership: 12.702%AIGH Capital Management LLCBought 496,183 shares on 2/12/2024Ownership: 10.289%Worth Venture Partners LLCSold 41,339 shares on 2/9/2024Ownership: 0.924%View All Institutional Transactions COYA Stock Analysis - Frequently Asked Questions Should I buy or sell Coya Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coya Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" COYA shares. View COYA analyst ratings or view top-rated stocks. What is Coya Therapeutics' stock price target for 2024? 2 Wall Street research analysts have issued 12-month price targets for Coya Therapeutics' shares. Their COYA share price targets range from $14.00 to $14.00. On average, they expect the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 75.2% from the stock's current price. View analysts price targets for COYA or view top-rated stocks among Wall Street analysts. How have COYA shares performed in 2024? Coya Therapeutics' stock was trading at $7.41 at the beginning of the year. Since then, COYA stock has increased by 7.8% and is now trading at $7.99. View the best growth stocks for 2024 here. Are investors shorting Coya Therapeutics? Coya Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 191,100 shares, an increase of 309.2% from the March 15th total of 46,700 shares. Based on an average trading volume of 94,200 shares, the short-interest ratio is currently 2.0 days. Currently, 1.5% of the company's shares are sold short. View Coya Therapeutics' Short Interest. When is Coya Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our COYA earnings forecast. How were Coya Therapeutics' earnings last quarter? Coya Therapeutics, Inc. (NASDAQ:COYA) announced its earnings results on Tuesday, March, 19th. The company reported $0.15 EPS for the quarter. The company had revenue of $6 million for the quarter. When did Coya Therapeutics IPO? Coya Therapeutics (COYA) raised $15 million in an initial public offering on Thursday, December 29th 2022. The company issued 3,050,000 shares at a price of $5.00 per share. How do I buy shares of Coya Therapeutics? Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:COYA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
